Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Harmony Biosciences Holdings Inc's Business Segments
Harmony Biosciences Holdings Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q2 FY2026
Reportable Segments
1
Largest Segment
Rare Neurological Diseases Segment
Total Revenue
$ 261
Regions Reported
-
Revenue Share by Reportable Segment - Q2 FY2026
- Rare Neurological Diseases Segment100%
Revenue by Reportable Segment - Q2 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Rare Neurological Diseases Segment | $ 261 | 100% |
Description of Harmony Biosciences Holdings Inc
Harmony Biosciences Holdings Inc is a clinical-stage biopharmaceutical company that was founded in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. The company is focused on developing and commercializing innovative therapies for patients with sleep and central nervous system disorders.
Harmony Biosciences Holdings Inc is primarily known for its lead product, WAKIX® (pitolisant), which was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations.
WAKIX represents a breakthrough in the treatment of narcolepsy as it works differently from existing treatments. It is a first-in-class medication that selectively targets the histamine 3 (H3) receptor, which is involved in the regulation of wakefulness and sleep. By activating this receptor, WAKIX increases histamine release in the brain, which helps to promote wakefulness.
Apart from WAKIX, Harmony Biosciences has a pipeline of other innovative compounds at various stages of development for central nervous system disorders. These include pitolisant, which is being evaluated for the treatment of patients with obstructive sleep apnea; and pitolisant-sodium oxybate, a combination therapy being developed for the treatment of narcolepsy.
Harmony Biosciences is also dedicated to bringing innovation and transformation to the field of sleep and central nervous system disorders. The company has a robust research and development program that is focused on identifying new molecular targets and developing new therapies to address unmet medical needs in the field.
In addition to developing innovative therapies, Harmony Biosciences is committed to improving the lives of patients with sleep and central nervous system disorders. The company collaborates with patient advocacy groups, healthcare professionals, and academic institutions to support research, education, and awareness of these disorders.
Harmony Biosciences Holdings Inc is primarily known for its lead product, WAKIX® (pitolisant), which was approved by the U.S. Food and Drug Administration (FDA) in 2019 for the treatment of excessive daytime sleepiness or cataplexy in adult patients with narcolepsy. Narcolepsy is a chronic neurological disorder characterized by excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations.
WAKIX represents a breakthrough in the treatment of narcolepsy as it works differently from existing treatments. It is a first-in-class medication that selectively targets the histamine 3 (H3) receptor, which is involved in the regulation of wakefulness and sleep. By activating this receptor, WAKIX increases histamine release in the brain, which helps to promote wakefulness.
Apart from WAKIX, Harmony Biosciences has a pipeline of other innovative compounds at various stages of development for central nervous system disorders. These include pitolisant, which is being evaluated for the treatment of patients with obstructive sleep apnea; and pitolisant-sodium oxybate, a combination therapy being developed for the treatment of narcolepsy.
Harmony Biosciences is also dedicated to bringing innovation and transformation to the field of sleep and central nervous system disorders. The company has a robust research and development program that is focused on identifying new molecular targets and developing new therapies to address unmet medical needs in the field.
In addition to developing innovative therapies, Harmony Biosciences is committed to improving the lives of patients with sleep and central nervous system disorders. The company collaborates with patient advocacy groups, healthcare professionals, and academic institutions to support research, education, and awareness of these disorders.
Harmony Biosciences Holdings Inc. is a biopharmaceutical company that is deeply committed to addressing the complex medical needs of patients suffering from central nervous system (CNS) disorders. The company has carved a niche in developing, producing, and commercializing innovative therapies primarily aimed at improving the quality of life for individuals with narcolepsy and related sleep disorders.
Product Offerings
1. WAKIXe (Pitolisant):
- Indication: WAKIXe is the first medication approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of excessive daytime sleepiness (EDS) in adults diagnosed with narcolepsy.
- Mechanism of Action: It operates as an orexin receptor antagonist, selectively targeting orexin receptors that regulate wakefulness and sleep. By modulating these receptors, WAKIXe helps promote wakefulness and reduce the symptoms associated with narcolepsy.
- Dosage and Administration: WAKIXe is available in two strengths: 5 mg and 9 mg. The recommended regimen is a once-daily oral dose taken in the morning, facilitating its effectiveness throughout the day.
- Clinical Benefits: Clinical trials demonstrate significant efficacy in managing EDS, as patients experienced increased wakefulness, diminished daytime sleepiness, and overall improved life satisfaction. Healthcare professionals often recommend WAKIXe for its role in enhancing daily functioning and the overall quality of life for patients.
2. Pitolisant (under development):
- Indication: Currently under FDA review, this formulation targets the treatment of cataplexy associated with narcolepsy in adult patients. Cataplexy manifests as sudden, temporary loss of muscle control, triggered by strong emotional stimuli.
- Mechanism of Action: Pitolisant acts as a selective histamine 3 (H3) receptor antagonist, modulating neurotransmitter release that affects wakefulness and sleep patterns. By inhibiting the H3 receptor, it promotes the release of histamine, which plays a critical role in maintaining wakefulness.
- Clinical Advantages: Preliminary clinical trials have shown promise, establishing Pitolisant as a potential breakthrough in the management of cataplexy, addressing a significant unmet need within the narcolepsy patient population.
Services and Patient-Focused Initiatives
Harmony Biosciences also recognizes that pharmaceutical care extends beyond just medication availability. Their patient support infrastructure is designed to enhance treatment adherence and address the holistic needs of patients:
1. Patient Support Programs:
- The company provides robust assistance aimed at helping patients navigate their treatment journeys. This includes connecting patients to financial assistance for their therapies, ensuring that cost is not a barrier to care.
- The support includes educational resources, personalized assistance for medication access, and tools that promote effective communication between patients and their healthcare providers.
2. Clinical Development:
- Harmony Biosciences invests continually in research and development (R&D) initiatives, emphasizing the importance of discovering and advancing additional therapeutic options for CNS disorders. This strong focus on R&D underlines the company’s commitment to innovation and excellence in therapeutics.
3. Disease Education:
- The company prioritizes the dissemination of educational resources aimed at various stakeholders, including patients, caregivers, and healthcare providers. These resources help to deepen the understanding of narcolepsy and other CNS disorders, informing patients about their conditions as well as the available treatment modalities.
4. Advocacy:
- Harmony actively collaborates with patient advocacy groups to raise awareness about the challenges faced by individuals living with CNS disorders. This advocacy work not only aims to support patients but also seeks to influence policy and enhance the allocation of resources for research and treatment.
Conclusion
In summary, Harmony Biosciences Holdings Inc. represents a key player in the biopharmaceutical landscape, particularly with its dedicated focus on CNS disorders such as narcolepsy. Through its current and developing product offerings, alongside a comprehensive range of patient support services and advocacy efforts, the company demonstrates a steadfast commitment to enhancing the lives of those impacted by these challenging and often life-altering conditions. The dual approach of providing effective medications while also supporting patient education and access to care reflects the broader mission of improving health outcomes in the CNS space.
Product Offerings
1. WAKIXe (Pitolisant):
- Indication: WAKIXe is the first medication approved by the U.S. Food and Drug Administration (FDA) specifically for the treatment of excessive daytime sleepiness (EDS) in adults diagnosed with narcolepsy.
- Mechanism of Action: It operates as an orexin receptor antagonist, selectively targeting orexin receptors that regulate wakefulness and sleep. By modulating these receptors, WAKIXe helps promote wakefulness and reduce the symptoms associated with narcolepsy.
- Dosage and Administration: WAKIXe is available in two strengths: 5 mg and 9 mg. The recommended regimen is a once-daily oral dose taken in the morning, facilitating its effectiveness throughout the day.
- Clinical Benefits: Clinical trials demonstrate significant efficacy in managing EDS, as patients experienced increased wakefulness, diminished daytime sleepiness, and overall improved life satisfaction. Healthcare professionals often recommend WAKIXe for its role in enhancing daily functioning and the overall quality of life for patients.
2. Pitolisant (under development):
- Indication: Currently under FDA review, this formulation targets the treatment of cataplexy associated with narcolepsy in adult patients. Cataplexy manifests as sudden, temporary loss of muscle control, triggered by strong emotional stimuli.
- Mechanism of Action: Pitolisant acts as a selective histamine 3 (H3) receptor antagonist, modulating neurotransmitter release that affects wakefulness and sleep patterns. By inhibiting the H3 receptor, it promotes the release of histamine, which plays a critical role in maintaining wakefulness.
- Clinical Advantages: Preliminary clinical trials have shown promise, establishing Pitolisant as a potential breakthrough in the management of cataplexy, addressing a significant unmet need within the narcolepsy patient population.
Services and Patient-Focused Initiatives
Harmony Biosciences also recognizes that pharmaceutical care extends beyond just medication availability. Their patient support infrastructure is designed to enhance treatment adherence and address the holistic needs of patients:
1. Patient Support Programs:
- The company provides robust assistance aimed at helping patients navigate their treatment journeys. This includes connecting patients to financial assistance for their therapies, ensuring that cost is not a barrier to care.
- The support includes educational resources, personalized assistance for medication access, and tools that promote effective communication between patients and their healthcare providers.
2. Clinical Development:
- Harmony Biosciences invests continually in research and development (R&D) initiatives, emphasizing the importance of discovering and advancing additional therapeutic options for CNS disorders. This strong focus on R&D underlines the company’s commitment to innovation and excellence in therapeutics.
3. Disease Education:
- The company prioritizes the dissemination of educational resources aimed at various stakeholders, including patients, caregivers, and healthcare providers. These resources help to deepen the understanding of narcolepsy and other CNS disorders, informing patients about their conditions as well as the available treatment modalities.
4. Advocacy:
- Harmony actively collaborates with patient advocacy groups to raise awareness about the challenges faced by individuals living with CNS disorders. This advocacy work not only aims to support patients but also seeks to influence policy and enhance the allocation of resources for research and treatment.
Conclusion
In summary, Harmony Biosciences Holdings Inc. represents a key player in the biopharmaceutical landscape, particularly with its dedicated focus on CNS disorders such as narcolepsy. Through its current and developing product offerings, alongside a comprehensive range of patient support services and advocacy efforts, the company demonstrates a steadfast commitment to enhancing the lives of those impacted by these challenging and often life-altering conditions. The dual approach of providing effective medications while also supporting patient education and access to care reflects the broader mission of improving health outcomes in the CNS space.